论文部分内容阅读
目的观察阿托伐他汀联合低分子肝素治疗短暂性脑缺血发作(TIA)的临床疗效。方法TIA患者147例,随机分为阿托伐他汀联合低分子肝素治疗组(A组n=37)、阿托伐他汀组(B组n=37)、低分子肝素组(C组n=36)、对照组(D组n=38),均采用常规治疗;A组加用阿托伐他汀20mg,每晚一次,连用21d和低分子肝素钙5000U,1次/12h,皮下注射,连用7d;B组加用阿托伐他汀20mg,每晚一次,连用21d;C组加用低分子肝素钙5000U,1次/12h,皮下注射,连用7d。观察各组有效率、治疗前后血小板计数、PT、APTT、血液流变学指标、血脂、纤维蛋白原的变化,随访TIA复发和向脑梗死进展情况。结果A、B、C、D四组有效率分别为89.2%、78.4%、80.6%、65.8%,A、B、C组和D组相比差异均有统计学意义(P<0.05),A组和B、C组差异有统计学意义(P<0.05),B组和C组差异无统计学意义(P>0.05)。结论阿托伐他汀以及低分子肝素治疗TIA疗效确切,阿托伐他汀联合低分子肝素治疗效果更佳,并可减少复发及向脑梗死发展。
Objective To observe the clinical efficacy of atorvastatin combined with low molecular weight heparin in the treatment of transient ischemic attack (TIA). Methods A total of 147 TIA patients were randomly divided into atorvastatin group and low molecular weight heparin group (n = 37 in group A), atorvastatin group (n = 37 in group B), low molecular weight heparin group (n = 36 ) And control group (n = 38 in group D). All patients in group A received atorvastatin 20 mg once a day for 21 days and low molecular weight heparin 5000U once a day for 12 hours. ; B group with atorvastatin 20mg, once night, once every 21d; C group with low molecular weight heparin 5000U, 1 / 12h, subcutaneous injection, once every 7d. The efficiency of each group, platelet count, PT, APTT, hemorheological indexes, blood lipids and fibrinogen were observed before and after treatment. Follow-up TIA recurrence and progression to cerebral infarction were observed. Results The effective rates of group A, B, C and D were 89.2%, 78.4%, 80.6% and 65.8% respectively. There was significant difference between group A, B, C and D (P <0.05) There was significant difference between group B and C (P <0.05), but there was no significant difference between group B and C (P> 0.05). Conclusions Atorvastatin and low molecular weight heparin are effective in treating TIA. Atorvastatin combined with low molecular weight heparin is more effective and can reduce the recurrence and development of cerebral infarction.